Beta Bionics (BBNX) Status Update summary

Commercial and product updates

• Launched the Bionic Portal, an online platform providing real-time, accessible clinical outcomes for healthcare providers prescribing iLet, aiming to boost prescriber confidence and adoption.

• Pharmacy channel strategy raised guidance for new patient starts to 22%-25% for the year, driven by plan adoption and operational efficiency, with lower out-of-pocket costs and no long-term hardware commitment for users.

• Pharmacy model generates about 3x the revenue over four years compared to DME, with financial benefits realized after 11 months, despite short-term margin headwinds.

Algorithm and clinical outcomes

• iLet’s adaptive closed-loop algorithm reduces A1C from an average baseline of 8.9% to 7.3%, with a tight distribution and low hypoglycemia rates, regardless of user engagement or provider type.

• The system enables similar outcomes for patients managed by endocrinologists and primary care providers, expanding access to those previously underserved.

• Even users who rarely announce meals achieve significant A1C reductions, indicating near fully closed-loop performance for a subset of users.

Patch pump (Mint) development and strategy

• Introduced Mint, a two-part patch pump with a reusable controller and disposable cartridge, designed for ease of use, minimal environmental waste, and pharmacy distribution.

• Mint will be controlled via an updated iLet app, requires no charging, and supports remote firmware updates for rapid feature and sensor compatibility rollouts.

• Commercial launch is targeted by end of 2027, with manufacturing and regulatory processes underway and a broad launch planned upon readiness.

• Mint’s cost structure is expected to be more favorable than competitors, with most expensive components in the durable part and disposables kept low-cost.